Published in World J Orthop on March 18, 2011
Pantoea agglomerans lipopolysaccharide maintains bone density in premenopausal women: a randomized, double-blind, placebo-controlled trial. Food Sci Nutr (2014) 1.38
Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res (2013) 0.93
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links. Clin Interv Aging (2013) 0.89
Effects of anti-tumor necrosis factor α agents on bone. Curr Opin Rheumatol (2012) 0.84
Trauma-induced heterotopic bone formation and the role of the immune system: A review. J Trauma Acute Care Surg (2016) 0.77
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
Minireview: the OPG/RANKL/RANK system. Endocrinology (2001) 4.47
The complex role of estrogens in inflammation. Endocr Rev (2007) 4.07
Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol (1990) 3.57
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A (2001) 2.56
Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A (1991) 2.44
Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun (1999) 2.28
IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest (2006) 2.15
Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest (1994) 2.00
Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science (1996) 1.95
Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum (2001) 1.85
Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A (2003) 1.75
IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood (2001) 1.72
A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum (2009) 1.70
IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A (2002) 1.65
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone (2008) 1.64
Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest (1994) 1.51
Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest (1994) 1.50
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood (2002) 1.47
Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest (2002) 1.47
T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res (2001) 1.43
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res (2007) 1.35
Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci U S A (2004) 1.32
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum (1989) 1.30
Human osteoclasts derive from CD14-positive monocytes. Br J Haematol (1999) 1.30
Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci U S A (1999) 1.26
Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Am J Pathol (1990) 1.25
Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol (2001) 1.22
CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther (2010) 1.17
Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol (2007) 1.16
Characterization of osteoclast precursors in human blood. Br J Haematol (2000) 1.14
Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res (2002) 1.13
An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci U S A (2005) 1.13
Dendritic cells at the osteo-immune interface: implications for inflammation-induced bone loss. J Bone Miner Res (2007) 1.11
Estrogen deficiency, T cells and bone loss. Cell Immunol (2007) 1.09
Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J (2004) 1.08
A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum (1997) 1.06
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood (2004) 1.02
Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J Cell Biochem (2007) 1.02
T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann N Y Acad Sci (2007) 1.01
Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas (1997) 1.00
IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One (2006) 0.95
Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol (2009) 0.94
MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR. Cell Signal (2010) 0.94
Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology (1994) 0.93
Oral mucosal dendritic cells and periodontitis: many sides of the same coin with new twists. Periodontol 2000 (2007) 0.92
T cells support osteoclastogenesis in an in vitro model derived from human periodontitis patients. J Periodontol (2005) 0.92
Immune system and bone metabolism: Does thymectomy influence postmenopausal bone loss in humans? Bone (2006) 0.91
17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol Endocrinol (2004) 0.90
Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. Oral Microbiol Immunol (2009) 0.87
Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol (2001) 0.87
Prolonged decrease of serum calcium concentration by murine gamma-interferon in hypercalcemic, human tumor (EC-GI)-bearing nude mice. Cancer Res (1992) 0.86
Osteoclastogenesis in peripheral blood mononuclear cell cultures of periprosthetic osteolysis patients and the phenotype of T cells localized in periprosthetic tissues. Biomaterials (2010) 0.85
Role of TNF-alpha producing T-cells in bone loss induced by estrogen deficiency. Minerva Med (2004) 0.85
Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). Cancer Immunol Immunother (1994) 0.84
CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation. Immunobiology (2008) 0.84
Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function. Immunology (2008) 0.83
Dendritic cells: a new player in osteoimmunology. Curr Mol Med (2009) 0.81
Effects of rhIL-7 on leukocyte subsets in mice: implications for antitumor activity. Immunol Ser (1994) 0.79
Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum (2005) 0.79
Osteoclasts direct bystander killing of cancer cells in vitro. Bone (2005) 0.78
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
The RAD-HOME project: a pilot study of home delivery of radiology services. Arch Intern Med (2011) 1.12
A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. PLoS One (2008) 1.02
Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J (2004) 0.93
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab (2004) 0.90
The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Exp Hematol (2003) 0.88
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci (2014) 0.84
Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J Immunol (2004) 0.82
Role of iron metabolism and oxidative damage in postmenopausal bone loss. Bone (2008) 0.82
Malnutrition in an elderly demented population living at home. Arch Gerontol Geriatr (2011) 0.81
The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother (2013) 0.80
Iloprost modulates the immune response in systemic sclerosis. BMC Immunol (2010) 0.80
Energy metabolism and the skeleton: Reciprocal interplay. World J Orthop (2012) 0.79
Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment. Calcif Tissue Int (2012) 0.78
Bone metastases in gastric cancer follow a RANKL-independent mechanism. Oncol Rep (2013) 0.78
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. Oncol Rep (2011) 0.78
Ability of ultrasound bone profile score (UBPS) to discriminate between fractured and not fractured osteoporotic women. Ultrasound Med Biol (2002) 0.77
The role of circulating bone cell precursors in fracture healing. Calcif Tissue Int (2010) 0.77
Cross-talk between T cells and osteoclasts in bone resorption. Bonekey Rep (2012) 0.77
Functional decline two weeks before hospitalization in an elderly population. Aging Clin Exp Res (2010) 0.77
Prevalence of postmenopausal osteoporosis in Italy and validation of decision rules for referring women for bone densitometry. Calcif Tissue Int (2013) 0.76
Stress in professional care-givers working with patients with dementia: a hypothesis-generating study. Aging Clin Exp Res (2010) 0.75
Short-term urine deoxypyridinoline biological variability in the first 5 years after menopause. Clin Chem (2005) 0.75
Microdamage accumulation changes according to animal mass: an intraspecies investigation. Calcif Tissue Int (2011) 0.75
X-ray, CT and DXA study of bone loss on medieval remains from North-West Italy. Radiol Med (2015) 0.75